Johnson & Johnson Comprehensive Income 2012-2026 | JNJ

Johnson & Johnson comprehensive income from 2012 to 2026. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
  • Johnson & Johnson comprehensive income for the quarter ending March 31, 2026 was $-14.930B, a 27.16% increase year-over-year.
  • Johnson & Johnson comprehensive income for 2025 was $-14.93B, a 27.16% increase from 2024.
  • Johnson & Johnson comprehensive income for 2024 was $-11.741B, a 6.27% decline from 2023.
  • Johnson & Johnson comprehensive income for 2023 was $-12.527B, a 3.39% decline from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Johnson & Johnson Annual Comprehensive Income
(Millions of US $)
2025 $-14,930
2024 $-11,741
2023 $-12,527
2022 $-12,967
2021 $-13,058
2020 $-15,242
2019 $-15,891
2018 $-15,222
2017 $-13,199
2016 $-14,901
2015 $-13,165
2014 $-10,722
2013 $-2,860
2012 $-5,810
2011 $-5,632
Johnson & Johnson Quarterly Comprehensive Income
(Millions of US $)
2025-12-31 $-14,930
2025-09-30 $-15,237
2025-06-30 $-14,305
2025-03-31 $-11,740
2024-12-31 $-11,741
2024-09-30 $-12,522
2024-06-30 $-11,253
2024-03-31 $-10,768
2023-12-31 $-12,527
2023-09-30 $-8,780
2023-06-30 $-13,135
2023-03-31 $-12,626
2022-12-31 $-12,967
2022-09-30 $-15,292
2022-06-30 $-13,843
2022-03-31 $-13,757
2021-12-31 $-13,058
2021-09-30 $-15,415
2021-06-30 $-15,100
2021-03-31 $-15,328
2020-12-31 $-15,242
2020-09-30 $-14,938
2020-06-30 $-15,533
2020-03-31 $-16,243
2019-12-31 $-15,891
2019-09-30 $-15,533
2019-06-30 $-14,969
2019-03-31 $-15,517
2018-12-31 $-15,222
2018-09-30 $-14,647
2018-06-30 $-14,777
2018-03-31 $-12,608
2017-12-31 $-13,199
2017-09-30 $-12,747
2017-06-30 $-13,234
2017-03-31 $-14,522
2016-12-31 $-14,901
2016-09-30 $-12,715
2016-06-30 $-12,707
2016-03-31 $-12,391
2015-12-31 $-13,165
2015-09-30 $-12,861
2015-06-30 $-12,054
2015-03-31 $-13,300
2014-12-31 $-10,722
2014-09-30 $-5,382
2014-06-30 $-3,007
2014-03-31 $-2,645
2013-12-31 $-2,860
2013-09-30 $-5,346
2013-06-30 $-6,810
2013-03-31 $-6,689
2012-12-31 $-5,810
2012-09-30 $-4,925
2012-06-30 $-6,204
2012-03-31 $-4,540
2011-12-31 $-5,632
2011-09-30 $-3,068
2011-06-30 $-1,192
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $574.358B $94.193B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
AbbVie (ABBV) United States $367.673B 20.79
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88